Federal legalization of cannabis would require Congress to pass a law removing marijuana from the federal controlled substances list, and no such law is currently on track to pass. What is moving is something narrower: a rulemaking process, accelerated by a December 2025 executive order, that would shift cannabis from Schedule I to Schedule III.1The White House. Increasing Medical Marijuana and Cannabidiol Research That shift matters, but it is not legalization. Understanding the gap between those two outcomes is the difference between expecting change that is coming and expecting change that is not.
Rescheduling Is Not Legalization
Two different mechanisms get confused in coverage of federal cannabis reform. They produce very different worlds.
Rescheduling moves cannabis to a lower tier within the Controlled Substances Act. The current proposal is Schedule III, alongside ketamine and anabolic steroids. Schedule III substances are recognized as having accepted medical use and lower abuse potential than the top two categories.2Office of the Law Revision Counsel. 21 USC 812 – Schedules of Controlled Substances But cannabis would still be a controlled substance. Most federal criminal penalties, the firearms ban on drug users, immigration consequences, and banking barriers all survive.
Descheduling removes cannabis from the schedules entirely. This is federal legalization in the sense most people mean it. Cannabis would then be treated more like alcohol: subject to federal regulation and taxation, but no longer carrying the penalties attached to controlled substances. Only descheduling resolves the full range of collateral consequences.
The Administrative Path: How Rescheduling Works
Rescheduling does not require a new statute. The Controlled Substances Act authorizes the Attorney General to move substances between schedules or remove them entirely.3Office of the Law Revision Counsel. 21 USC 811 – Authority and Criteria for Classification of Substances
The Attorney General, through the DEA, first requests a scientific and medical evaluation from the Department of Health and Human Services. HHS conducts that evaluation through the FDA, looking at abuse potential, medical use, and safety. HHS’s scientific and medical findings are binding on the DEA. If HHS recommends against scheduling a substance, the DEA cannot schedule it.4Department of Justice Office of Legal Counsel. Questions Related to the Potential Rescheduling of Marijuana
After the HHS recommendation, the DEA runs formal rulemaking: a proposed rule in the Federal Register, a public comment period, and an administrative hearing before any final rule takes effect. The Department of Justice published its proposed rule to move cannabis to Schedule III in May 2024. That proposal drew nearly 43,000 comments and, as of the December 2025 executive order, was still awaiting an administrative law hearing. The executive order directs the Attorney General to complete the process “in the most expeditious manner,” though no firm timeline is set.1The White House. Increasing Medical Marijuana and Cannabidiol Research
The Legislative Path: How Descheduling Works
Full federal legalization requires Congress to pass a bill that removes cannabis from the controlled substances schedules, and the President must sign it. This is the only route that resolves all the collateral consequences in one instrument: taxes, banking, criminal penalties, firearms, immigration, and bankruptcy access.
The most prominent descheduling proposal was the Marijuana Opportunity Reinvestment and Expungement (MORE) Act, which passed the House in 2022 and did not advance in the Senate.5Congress.gov. H.R.3617 – 117th Congress (2021-2022) – MORE Act It would have removed cannabis from the schedules entirely, created a process to expunge prior federal cannabis convictions, established a trust fund for communities affected by drug enforcement, and barred denial of federal benefits or immigration relief based on cannabis use. No comparable descheduling bill has advanced in the current Congress. The legislative focus has shifted toward rescheduling bills and standalone banking reform.
A descheduling bill would follow the standard legislative path: introduction, committee markup, floor votes in both chambers, conference to reconcile differences, and presidential signature. Because it removes cannabis from the CSA outright, Congress would have the chance to build a replacement regulatory and tax framework into the same legislation.
A Treaty Problem That Rarely Gets Discussed
Any rescheduling effort runs into the 1961 Single Convention on Narcotic Drugs. Cannabis is controlled under that treaty, and the CSA requires the United States to maintain scheduling sufficient to meet its treaty obligations. A federal appeals court ruled in 1977 that only Schedule I or Schedule II placement satisfies those obligations, because the treaty’s import and export permit and quota requirements have no equivalent in Schedules III through V.6Drug Enforcement Administration. Preliminary Note Regarding Treaty Considerations
The current proposal to move cannabis to Schedule III therefore faces a potential legal challenge on treaty grounds. The DOJ would need to distinguish the current effort from the 1977 ruling, argue the treaty itself has evolved, or Congress would need to address the conflict through legislation. This adds another layer of uncertainty to whether the administrative process will survive judicial review.
What Actually Changes for Cannabis Businesses
The near-term tax impact is the biggest concrete gain from rescheduling. Under Internal Revenue Code Section 280E, no business deductions or credits are allowed for any trade or business trafficking in a Schedule I or II controlled substance.7Office of the Law Revision Counsel. 26 USC 280E – Expenditures in Connection With the Illegal Sale of Drugs State-legal dispensaries and cultivators currently cannot deduct rent, payroll, or advertising. They can only deduct cost of goods sold. Some cannabis operators have reported effective federal tax rates reaching 80%.
Moving cannabis to Schedule III would immediately make Section 280E inapplicable, because the statute only reaches Schedule I and II substances.8Congress.gov. Rescheduling Marijuana – Implications for Criminal and Collateral Consequences Businesses could then take the same deductions available to any other legal enterprise. For a company with $100,000 in revenue and $80,000 in operating expenses, the difference is roughly $21,000 in federal tax on gross revenue versus $4,200 on net income.
Banking is a different story. Cannabis businesses in most states operate largely in cash because banks and credit unions face federal money-laundering exposure by handling funds from a federally illegal enterprise. Rescheduling to Schedule III does not fix this. Cannabis would remain a controlled substance, and the anti-money laundering statutes and banking compliance obligations that create the current barrier are separate from the scheduling question. Resolving banking access requires standalone legislation like the SAFER Banking Act, which has drawn bipartisan support in Congress but has not been enacted as of 2026. Full descheduling would address the underlying trigger.
Bankruptcy access follows a similar pattern. Federal bankruptcy courts have consistently dismissed petitions from cannabis businesses on the reasoning that a debtor actively violating federal law cannot receive protection under the Bankruptcy Code, and trustees cannot administer assets that are illegal under federal law. Rescheduling to Schedule III would help, but the extent of relief is uncertain because cannabis manufacturing and distribution would still be regulated under the CSA. And interstate commerce remains barred: cannabis currently cannot cross state lines, even between two states that have both legalized it. Only descheduling would open a national market.
What Rescheduling Does Not Fix
This is where expectations often outrun the reality of what an administrative move accomplishes.
Most federal criminal penalties for cannabis are written specifically for marijuana in the CSA and are not tied to the Schedule I classification. Penalties for manufacturing, distributing, and possessing cannabis would remain exactly the same if cannabis moves to Schedule III.8Congress.gov. Rescheduling Marijuana – Implications for Criminal and Collateral Consequences The state-federal conflict persists. A few narrow provisions do turn on Schedule I status; for example, the federal crime of placing written advertisements to buy or distribute a Schedule I substance would no longer apply to cannabis. But the major trafficking and possession penalties do not change. Only descheduling eliminates the federal criminal prohibitions that conflict with state legalization, and only a descheduling bill can build in expungement and resentencing provisions of the kind the MORE Act included.
Firearms law follows the same logic. Federal law prohibits any “unlawful user of or addicted to any controlled substance” from possessing a firearm or ammunition, with a penalty reaching 15 years.9Office of the Law Revision Counsel. 18 USC 922 – Unlawful Acts The prohibition covers users of any controlled substance, not just Schedule I substances. As long as someone is using cannabis without an FDA-approved prescription, and no such pathway currently exists for cannabis flower, they remain an unlawful user. The Supreme Court heard arguments in early 2026 on whether the statute’s application to cannabis users violates the Second Amendment. No ruling has been issued.
Immigration consequences also survive rescheduling. Under the Immigration and Nationality Act, any conviction for violating a law related to a controlled substance, or even an admission of conduct that constitutes such a violation, can make a person inadmissible or deportable regardless of state legality.10U.S. Department of State. 9 FAM 302.4 – Ineligibility Based on Controlled Substance Violations A non-citizen who admits to cannabis use in a state where it is legal can still face visa denial, refusal of entry, or removal proceedings. Customs and Border Protection considers involvement in the cannabis industry in admissibility determinations, so working at a licensed dispensary can trigger problems. Only descheduling removes cannabis from the controlled substance definition that triggers these provisions.
Federal employment testing is likewise untouched. In March 2026, HHS confirmed that drug testing panels for federal workplace programs will continue to include marijuana, despite the pending rescheduling effort. Even under Schedule III, federal agencies retain broad authority to prohibit employee drug use and test for it. Private-sector employers in many states are also free to maintain drug-free workplace policies, though state laws vary.
If Congress Ever Deschedules, What Fills the Gap
Descheduling would require Congress to build a new federal regulatory apparatus, or the market would move into a vacuum. The model most often proposed borrows from alcohol and tobacco regulation. The FDA would likely oversee product safety, labeling, and manufacturing standards, and the Alcohol and Tobacco Tax and Trade Bureau has been proposed to handle licensing and tax collection.
On taxation, the Marijuana Revenue and Regulation Act proposed a federal excise tax starting at 10% of sale price in the first two years, rising to 15%, 20%, and 25% in subsequent years, then converting to a per-ounce rate tied to prevailing market prices.11United States Senate Committee on Finance. Marijuana Revenue and Regulation Act Summary The gradual approach is meant to avoid crushing businesses that are already heavily taxed at the state level and to account for price drops that would follow descheduling as competition and interstate commerce expand.
Federal quality and safety standards would also need to address testing for pesticides, heavy metals, and potency, where states currently set their own limits with significant variation. A national standard would create uniformity, though compliance costs could weigh on smaller operators used to less stringent state rules.
For now, the practical reality is that the rescheduling process is what is moving. If it completes, cannabis businesses get a major tax cut and the industry gains legitimacy under FDA-regulated medical use. Everything else the reform conversation has promised, from firearms rights to immigration safety to a legal national market, waits on Congress.